安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Laduviglusib (CHIR-99021) | GSK-3 Inhibitor | MedChemExpress
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α β inhibitor with IC50 s of 10 nM and 6 7 nM Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases Laduviglusib is also a potent Wnt β-catenin signaling pathway activator
- CHIR-99021 (Laduviglusib) | GSK-3 Inhibitor | WNT Activator | CAS . . .
Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 values of 10 nM and 6 7 nM, respectively It does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs
- Laduviglusib | C22H18Cl2N8 | CID 9956119 - PubChem
Laduviglusib | C22H18Cl2N8 | CID 9956119 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety hazards toxicity information, supplier lists, and more
- CHIR99021 (CT 99021, Laduviglusib, CAS Number: 252917-06-9) | Cayman . . .
CHIR99021 activates glycogen synthesis in CHO- IR cells (EC 50 = 0 763 μM) and in isolated type 1 diabetic rat skeletal muscle A single oral dose (30 mg kg) of CHIR99021 enhances in vivo glucose metabolism in a rodent model of type 2 diabetes
- Laduviglusib - Drug Targets, Indications, Patents - Synapse
Our findings collectively present a transgene-free and chemical-only approach for the direct reprogramming of ISMCs into neuron-like cells This method offers an alternative strategy for replenishing the ENS in cases of HSCR
- Laduviglusib: Uses, Interactions, Mechanism of Action | DrugBank
Laduviglusib is a small molecule drug Laduviglusib has a monoisotopic molecular weight of 464 1 Da
- NCATS Inxight Drugs — LADUVIGLUSIB
CHIR 99021 is a selective, pyridimidine-based, glycogen synthase kinase 3 inhibitor that is effective at low nanomolar concentrations in enzyme assays and submicromolar concentrations in isolated cells and tissues Chiron was developing CHIR 99021 for potential use in the treatment of type 2 diabetes mellitus
- Laduviglusib: A GSK3β Inhibitor with Potential Across Multiple Diseases
Laduviglusib, a potent GSK3β inhibitor, has emerged as a promising therapeutic agent for a variety of diseases, including neurodegenerative disorders, cancer, and metabolic diseases
|
|
|